ESTRO 2024 - Abstract Book

S1002

Clinical - Gynaecology

ESTRO 2024

Cervical carcinoma is the fourth most common malignancy in women worldwide. The majority is caused by infection with high-risk types of human papillomavirus (HPV). The reason why not all HPV-infected women actually develop the disease suggests that various immunological factors play a role in this setting. Studies have shown correlations between body mass index (BMI) and the risk of developing malignant diseases. A higher fat mass could have a negative effect on tumour development due to an inflammation-promoting metabolism. We investigated anthropometric measurements and metabolic-immunological parameters to identify factors influencing the overall survival (OS) of patients with locally advanced cervical cancer (LACC) undergoing radio chemotherapy.

Material/Methods:

The data of the prospective, randomised, international, multicentre "Uterus-11" trial1 including patients with cervical cancer FIGO 2009 stage IIB–IVA undergoing primary radio-chemotherapy were analysed. We collected and calculated BMI (body mass index), leucocytes and mGPS (modified Glasgow Prognostic Score based on CRP and albumin, score 0 corresponds to a non-inflammatory status) from the patient files. Using imaging data of the radiotherapy planning CTs and the volume imaging program "VINCI"2, we measured and calculated WHR (waist hip ratio), RFM (relative fat mass), PMI (psoas muscle index) and intrapelvic fat distribution, see Figure 1 . We used cut-off values already established or defined by ROC analyses and SPSS v.28 and R v.4.1.2 for statistical analyses. Survival endpoints were defined as the time from randomisation to relapse or death from any cause. Survival rates and related survival curves were estimated using the Kaplan–Meier method, and curve comparisons were performed using the log rank test.

Results: